Loading...
Loading...
Genomic Health, Inc.
GHDX today announced that it has started a large clinical validation study of its prostate cancer test. The study, being performed in collaboration with leading prostate cancer researchers at the University of California, San Francisco, is designed to determine if a multi-gene test can help distinguish aggressive disease requiring surgery from less aggressive disease that may undergo active surveillance in patients with early-stage prostate cancer.
The study will utilize Genomic Health's proprietary RT-PCR process for analyzing very small amounts of formalin-fixed paraffin-embedded (FFPE) prostate tissue obtained by needle biopsy prior to removal of the prostate. Complete results are expected to be presented at the end of this year or early next year, and if positive, are expected to support the launch of the Oncotype DX® prostate cancer test in 2013.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in